Background Surgically created arteriovenous (AV) grafts are the most common type of hemodialysis vascular access in the United States, but fail frequently due to the development of venous stenosis. The Dialysis Access Consortium (DAC) Aggrenox Prevention of Access Stenosis Trial tests the hypothesis that Aggrenox (containing dipyridamole and aspirin) can prevent stenosis and prolong survival of arteriovenous grafts.
Methods This is a multicenter, randomized, double-blind, placebo-controlled trial that will enroll 1056 subjects over four years with one-half year follow-up. Subjects undergoing placement of a new AV graft for hemodialysis are randomized to treatment with Aggrenox or placebo immediately following access surgery. The primary outcome is primary unassisted patency defined as the time from access placement until thrombosis or an access procedure carried out to maintain or restore patency. The major secondary outcome is cumulative access patency. Monthly access flow monitoring is incorporated in the study design to enhance detection of a hemodynamically significant access stenosis before it leads to thrombosis.
Results This paper describes the key issues in trial design, broadly including: 1) ethical issues surrounding the study of a clinical procedure that, although common, is no longer the clinical intervention of choice; 2) acceptable risk (bleeding) from the primary intervention; 3) inclusion of subjects already receiving a portion of the study intervention; 4) inclusion of subjects with incident rather than prevalent qualifying clinical conditions; 5) timing of the study intervention to balance safety and efficacy concerns; and 6) the selection of primary and secondary study endpoints.
Conclusions This is the first, large, multicenter trial evaluating a pharmacologic approach to prevent AV graft stenosis and failure, an important and costly problem in this patient population. Numerous design issues were addressed in implementing the trial and these will form a roadmap for future trials in this area.
Get full access to this article
View all access options for this article.
References
1.
1. US Renal Data System, USRDS 2003 Annual Data Report:Atlas of End-Stage Renal Disease in the United States. National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Disease; Bethesda, MD, 2003. Retrieved from http://www.usrds.org/adr_2003.htm
2.
2. Miller PE, Carlton D, Deierhoi MH, Redden DT, Allon M. Natural history of arteriovenous grafts in hemodialysis patients. Am J Kidney Dis2000; 36: 68–74.
4. Cinat ME, Hopkins J, Wilson SE. A prospective evaluation of PTFE graft patency and surveillance techniques in hemodialysis access. Ann Vasc Surg1999; 13: 191–198.
6. Feldman HI, Kobrin S, Wasserstein A. Hemodialysis vascular access morbidity. J Am Soc Nephrol1996; 7: 523–535.
7.
7. US Renal Data System: USRDS 1997 Annual Data Report. The economic cost of ESRD, vascular access procedures, and Medicare spending for alternative modalities of treatment. Am J Kidney Dis1997; 30: S160–s177.
8.
8. Windus DW. Permanent vascular access: a nephrologist's view. Am J Kidney Dis1993; 21: 457–471.
9.
9. Schwab SJ, Harrington JT, Singh A, Roher R, Shohaib SA, Perrone RD et al. Vascular access for hemodialysis. Kidney Int1999; 55: 2078–2090.
10.
10. Kanterman RY, Vesely TM, Pilgram TK, Guy BW, Windus DW, Picus D. Dialysis access grafts: anatomic location of venous stenosis and results of angioplasty. Radiology1995; 195: 135–139.
11.
11. Swedberg SH, Brown BG, Sigley R, Wight TN, Gordon D, Nicholls SC. Intimal fibromuscular hyperplasia at the venous anastomosis of PTFE grafts in hemodialysis patients. Clinical, immunocytochemical, light and electron microscopic assessment. Circulation1989; 80: 1726–1736.
12.
12. Rekhter M, Nicholls S, Ferguson M, Gordon D.Cell proliferation in human arteriovenous fistulas used for hemodialysis. Arterioscler Thromb1993; 13: 609–617.
13.
13. Hofstra L, Tordoir JH, Kitslaar PJ, Hoeks AP, Daemen MJ. Enhanced cellular proliferation in intact stenotic lesions derived from human arteriovenous fistulas and peripheral bypass grafts. Does it correlate with flow parameters?Circulation1996; 94: 1283–1290.
14.
14. Roy-Chaudhury P, Whiting JF, Miller MA, Reaves A, Denman D, Munda R et al. Neointimal hyperplasia and hemodialysis access dysfunction: a pathogenetic role for cytokines, matrix proteins, and specific cell types. In Henry ML ed. Vascular Access for Hemodialysis. Chicago IL: W.L. Gore & Associates and Precept Press, 1999: 45–53.
15.
15. Kaufman JS, O'Connor TZ, Zhang JH, Cronin RE, Fiore LD, Ganz MB et al. Randomized controlled trial of clopidogrel plus aspirin to prevent hemodialysis access graft thrombosis. J Am Soc Nephrol2003; 14: 2313–2321.
16.
16. Crowther MA, Clase CM, Margetts PJ, Julian J, Lambert K, Sneath D et al. Low-intensity warfarin is ineffective for the prevention of PTFE graft failure in patients on hemodialysis: a randomized controlled trial. J Am Soc Nephrol2002; 13: 2331–2337.
17.
17. Sreedhara R, Himmelfarb J, Lazarus JM, Hakim RM. Anti-platelet therapy in graft thrombosis: results of a prospective, randomized, double-blind study. Kidney Int1994; 45: 1477–1483.
18.
18. Schmitz PG, McCloud LK, Reikes ST, Leonard CL, Gellens ME. Prophylaxis of hemodialysis graft thrombosis with fish oil: double-blind, randomized, prospective trial. J Am Soc Nephrol2002; 13: 184–190.
19.
19. FitzGerald GA. Dipyridamole. N Engl J Med1987; 316: 1247–1257.
20.
20. Diener HC, Cunha L, Forbes C, Sivenius J, Smets P, Lowenthal A. European Stroke Prevention Study. 2. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke. J Neurol Sci1996; 143: 1–13.
22. Dubey RK, Gillespie DG, Shue H, Jackson EK.A(2B) receptors mediate antimitogenesis in vascular smooth muscle cells. Hypertension2000; 35: 267–272.
23.
23. Ingerman-Wojenski CM, Silver MJ. Model system to study interaction of platelets with damaged arterial wall. II. Inhibition of smooth muscle cell proliferation by dipyridamole and AH-P719. Exp Mol Pathol1988; 48: 116–134.
24.
24. Singh JP, Rothfuss KJ, Wiernicki TR, Lacefield WB, Kurtz WL, Brown RF et al. Dipyridamole directly inhibits vascular smooth muscle cell proliferation in vitro and in vivo: implications in the treatment of restenosis after angioplasty. J Am Coll Cardiol1994; 23: 665–671.
25.
25. Chesebro JH, Fuster V, Elveback LR, Clements IP, Smith HC, Holmes DR, Jr et al. Effect of dipyridamole and aspirin on late vein-graft patency after coronary bypass operations. N Engl J Med1984; 310: 209–214.
26.
26. Goldman S, Copeland J, Moritz T et al. Saphenous vein graft patency 1 year after coronary artery bypass surgery and effects of antiplatelet therapy. Results of a Veterans Administration Cooperative Study. Circulation1989; 80: 1190–1197.
27.
27. Himmelfarb J, Couper L. Dipyridamole inhibits PDGF- and bFGF-induced vascular smooth muscle cell proliferation. Kidney Int1997; 52: 1671–1677.
31. Besarab A, Lubkowski T, Frinak S, Ramanathan S, Escobar F. Detecting vascular access dysfunction. Asaio J1997; 43: M539–M543.
32.
32. Depner TA, Krivitski NM. Clinical measurement of blood flow in hemodialysis access fistulae and grafts by ultrasound dilution. Asaio J1995; 41: M745–M749.
33.
33. Krivitski NM. Theory and validation of access flow measurement by dilution technique during hemodialysis. Kidney Int1995; 48: 244–250.
34.
34. Cox DR. Regression models and life tables. J Royal Statist Soc, Series B1972; 34: 187–220.
35.
35. Kalman PG, Pope M, Bhola C, Richardson R, Sniderman KW. A practical approach to vascular access for hemodialysis and predictors of success. J Vasc Surg1999; 30: 727–733.
36.
36. Lazarides MK, Iatrou CE, Karanikas ID et al.Factors affecting the lifespan of autologous and synthetic arteriovenous access routes for haemodialysis. Eur J Surg1996; 162: 297–301.
37.
37. Woods JD, Turenne MN, Strawderman RL, Young EW, Hirth RA, Port FK et al. Vascular access survival among incident hemodialysis patients in the United States. Am J Kidney Dis1997; 30: 50–57.
38.
38. Diskin CJ, Stokes TJ, Thomas SG et al. An analysis of the effect of routine medications on hemodialysis vascular access survival. Nephron1998; 78: 365–368.
39.
39. Anonymous. Collaborative overview of randomised trials of antiplatelet therapy – I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Antiplatelet Trialists' Collaboration. BMJ1994; 308: 81–106.
40.
40. Gibbs CR, Lip GY. Do we still need dipyridamole?Br J Clin Pharmacol1998; 45: 323–328.
41.
41. Lakatos E. Sample sizes based on the log-rank statistic in complex clinical trials. Biometrics1988; 44: 229–241.
42.
42. Eknoyan G, Beck GJ, Cheung AK et al. Effect of dialysis dose and membrane flux in maintenance hemodialysis. N Engl J Med2002; 347: 2010–2019.
43.
43. Wang SK, Tsiatis AA. Approximately optimal one-parameter boundaries for group sequential trials. Biometrics1987; 43: 193–199.
44.
44. National Kidney Foundation. Disease Outcomes Quality Initiative (DOQI). Clinical practice guidelines for vascular access. Am J Kidney Dis1997; 30: S150–S191.
45.
45. D'Cunha PT, Besarab A. Vascular access for hemodialysis: 2004 and beyond. Curr Opin Nephrol Hypertens2004; 13: 623–629.
46.
46. Rayner HC, Besarab A, Brown WW, Disney A, Saito A, Pisoni RL. Vascular access results from the Dialysis Outcomes and Practice Patterns Study (DOPPS): performance against Kidney Disease Outcomes Quality Initiative (K/DOQI) Clinical Practice Guidelines. Am J Kidney Dis2004; 44: 22–26.
47.
47. Collins A, Kasiske B, Herzog C et al. Excerpts from the United States Renal Data System 2004 annual data report: atlas of end-stage renal disease in the United States. Am J Kidney Dis2005; 45: S29–S40.
48.
48. Lee T, Barker J, Allon M. Associations with predialysis vascular access management. Am J Kidney Dis2004; 43: 1008–1013.
49.
49. Oliver MJ, Rothwell DM, Fung K, Hux JE, Lok CE.Late creation of vascular access for hemodialysis and increased risk of sepsis. J Am Soc Nephrol2004; 15: 1936–1942.
50.
50. Xue JL, Dahl D, Ebben JP, Collins AJ. The association of initial hemodialysis access type with mortality outcomes in elderly Medicare ESRD patients. Am J Kid Dis2003; 42: 1013–1019.
51.
51. Gaspari F, Vigano G, Orisio S, Bonati M, Livio M, Remuzzi G. Aspirin prolongs bleeding time in uremia by a mechanism distinct from platelet cyclooxygenase inhibition. J Clin Invest1987; 79: 1788–1797.
52.
52. Harter HR, Burch JW, Majerus PW et al. Prevention of thrombosis in patients on hemodialysis by low-dose aspirin. N Engl J Med1979; 301: 577–579.
53.
53. Remuzzi G, Mingardi G, Mecca G, Donati MB, de Gaetano G. Does aspirin precipitate major gastrointestinal bleeding in patients on haemodialysis?Lancet1977; 2: 359–360.
54.
54. Kooistra MP, van Es A, Marx JJ, Hertsig ML, Struyvenberg A. Low-dose aspirin does not prevent thrombovascular accidents in low-risk haemodialysis patients during treatment with recombinant human erythropoietin. Nephrol Dial Transplant1994; 9: 1115–1120.
55.
55. Domoto DT, Bauman JE, Joist JH. Combined aspirin and sulfinpyrazone in the prevention of recurrent hemodialysis vascular access thrombosis. Thromb Res1991; 62: 737–743.
56.
56. Saran R, Dykstra DM, Wolfe RA et al. Association between vascular access failure and the use of specific drugs: the Dialysis Outcomes and Practice Patterns Study (DOPPS). Am J Kidney Dis2002; 40: 1255–1263.
57.
57. Besarab A, Sullivan KL, Ross RP, Moritz MJ. Utility of intra-access pressure monitoring in detecting and correcting venous outlet stenoses prior to thrombosis. Kidney Int1995; 47: 1364–1373.
58.
58. Schwab SJ, Oliver MJ, Suhocki P, McCann R.Hemodialysis arteriovenous access: Detection of stenosis and response to treatment by vascular access blood flow. Kidney Int2001; 59: 358–362.
59.
59. Besarab A, Samarapungavan D. Measuring the adequacy of hemodialysis access. Curr Opin Nephrol Hypertens1996; 5: 527–531.
60.
60. Pepe MS, Mori M. Kaplan-Meier, marginal or conditional probability curves in summarizing competing risks failure time data?Stat Med1993; 12: 737–751.
61.
61. Shen Y, Cheng SC. Confidence bands for cumulative incidence curves under the additive risk model. Biometrics1999; 55: 1093–1100.
62.
62. Krivitski NM. Theory and validation of access flow measurement by dilution technique during hemodialysis. Kidney Int1995; 48: 244–250.
